{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:20:34Z","timestamp":1788776434725,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T00:00:00Z","timestamp":1326067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T00:00:00Z","timestamp":1326067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1038\/leu.2012.5","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T14:13:48Z","timestamp":1326118428000},"page":"1475-1481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"26","author":[{"given":"H","family":"Pfeifer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Wystub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Wassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Binckebanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Giagounidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Wunderle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O G","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,9]]},"reference":[{"key":"BFleu20125_CR1","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109: 3676\u20133688.","journal-title":"Blood"},{"key":"BFleu20125_CR2","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, D\u00fchrsen U et al. Imatinib compared with Chemotherapy as Front-Line Treatment of Elderly Patients with Philadelphia Chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). Cancer 2007; 109: 2068\u20132076.","journal-title":"Cancer"},{"key":"BFleu20125_CR3","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O\u2019Brien S, Giles FJ, Kornblau SM et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396\u20134407.","journal-title":"Blood"},{"key":"BFleu20125_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/sj.leu.2403886","volume":"19","author":"KH Lee","year":"2005","unstructured":"Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509\u20131516.","journal-title":"Leukemia"},{"key":"BFleu20125_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460\u2013466.","journal-title":"J Clin Oncol"},{"key":"BFleu20125_CR6","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108: 1469\u20131477.","journal-title":"Blood"},{"key":"BFleu20125_CR7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038\u20131042.","journal-title":"N Engl J Med"},{"key":"BFleu20125_CR8","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965\u20131971.","journal-title":"Blood"},{"key":"BFleu20125_CR9","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2003-01-0154","volume":"103","author":"B Wassmann","year":"2004","unstructured":"Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, G\u00f6kbuget N, Atta J et al. Early prediction of response in patients with relapsed or refractory Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib mesylate (Glivec). Blood 2004; 103: 1495\u20131498.","journal-title":"Blood"},{"key":"BFleu20125_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A de Labarthe","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S et al. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408\u20131413.","journal-title":"Blood"},{"key":"BFleu20125_CR11","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","volume":"20","author":"A Delannoy","year":"2006","unstructured":"Delannoy A, Delabesse E, Lheritier V, Castaigne S, Rigal-Huguet F, Raffoux E et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20: 1526\u20131532.","journal-title":"Leukemia"},{"key":"BFleu20125_CR12","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","volume":"99","author":"WK Hofmann","year":"2002","unstructured":"Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860\u20131862.","journal-title":"Blood"},{"key":"BFleu20125_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N von Bubnoff","year":"2002","unstructured":"von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487\u2013491.","journal-title":"Lancet"},{"key":"BFleu20125_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/cncr.23666","volume":"113","author":"D Jones","year":"2008","unstructured":"Jones D, Thomas D, Yin CC, O\u2019Brien S, Cortes JE, Jabbour E et al. Kinase domain point mutations in Philadelphia Chromosome positive acute lymphoblastic leukemia emerge after therapy with bcr-abl kinase inhibitors. Cancer 2008; 113: 985\u2013994.","journal-title":"Cancer"},{"key":"BFleu20125_CR15","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472\u20133475.","journal-title":"Blood"},{"key":"BFleu20125_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"H Pfeifer","year":"2007","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110: 727\u2013734.","journal-title":"Blood"},{"key":"BFleu20125_CR17","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL Kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients. Clin Cancer Res 2006; 12: 7374\u20137379.","journal-title":"Clin Cancer Res"},{"key":"BFleu20125_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2002-06-1756","volume":"102","author":"WK Hofmann","year":"2003","unstructured":"Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 2003; 102: 659\u2013661.","journal-title":"Blood"},{"key":"BFleu20125_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3324\/haematol.2010.034173","volume":"96","author":"S Soverini","year":"2011","unstructured":"Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011; 96: 552\u2013557.","journal-title":"Haematologica"},{"key":"BFleu20125_CR20","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1128\/MCB.02202-05","volume":"26","author":"IJ Griswold","year":"2006","unstructured":"Griswold IJ, MacPartlin M, Bumm T, Goss VL, O\u2019Hare T, Lee KA et al. Kinase domain mutants of BCR-ABL exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082\u20136093.","journal-title":"Mol Cell Biol"},{"key":"BFleu20125_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.leu.2402889","volume":"17","author":"N von Bubnoff","year":"2003","unstructured":"von Bubnoff N, Peschel C, Duyster J . Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 2003; 17: 829\u2013838.","journal-title":"Leukemia"},{"key":"BFleu20125_CR22","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/leu.2008.180","volume":"22","author":"O Pelz-Ackermann","year":"2008","unstructured":"Pelz-Ackermann O, Cross M, Pfeifer H, Deininger M, Wang SY, Al-Ali HK et al. Highly sensitive and quantitative detection of bcr-abl kinase domain mutation by ligation PCR. Leukemia 2008; 22: 2288\u20132291.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu20125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20125","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:13:18Z","timestamp":1648739598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu20125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,9]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["BFleu20125"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,9]]},"assertion":[{"value":"14 December 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OG Ottmann received research support and honoraria for advisory board activities and scientific presentations from Novartis and Bristol-Myers-Squibb. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}